Ultrasensitive detection of KRAS2 mutations in bile and serum from patients with biliary tract carcinoma using LigAmp technology

Journal of Molecular Diagnostics

Volumn 11, Issue 6, 2009, Pages 583-589

  Shi, Chanjuan ^a   Chandrasekaran, Arjun ^a   Thuluvath, Paul J ^a,b   Karikari, Collins ^a   Argani, Pedram ^a   Goggins, Michael ^a   Maitra, Anirban ^a   Eshleman, James R ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b MERCY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BILE; BILE DUCT CARCINOMA; BILIARY TRACT DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA ISOLATION; DNA SEQUENCE; GENETIC PROCEDURES; HUMAN; LIGAMP; ONCOGENE K RAS; ONCOGENE K RAS 2; POINT MUTATION; POLYMERASE CHAIN REACTION; SERUM;

EID: 70350469237     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.2353/jmoldx.2009.090061     Document Type: Article

References (31)

1. Patel T: Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001, 33:1353-1357 (Pubitemid 32496970)
2. Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BJ, Youssef BM, Klimstra D, Blumgart LH: Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001, 234:507-517; discussion 517-1509 (Pubitemid 32946713)
3. Gores GJ: Cholangiocarcinoma: current concepts and insights. Hepatology 2003, 37:961-969
4. Freeny PC: Computed tomography in the diagnosis and staging of cholangiocarcinoma and pancreatic carcinoma, Ann Oncol 1999, 10 Suppl 4:12-17
5. van Leeuwen DJ, Reeders JW: Primary sclerosing cholangitis and cholangiocarcinoma as a diagnostic and therapeutic dilemma. Ann Oncol 1999, 10 Suppl 4:89-93
6. Sturm PD, Rauws EA, Hruban RH, Caspers E, Ramsoekh TB, Huibregtse K, Noorduyn LA, Offerhaus GJ: Clinical value of K-ras codon 12 analysis and endobiliary brush cytology for the diagnosis of malignant extrahepatic bile duct stenosis. Clin Cancer Res 1999, 5:629-635 (Pubitemid 29131974)
7. Wistuba II, Miquel JF, Gazdar AF, Albores-Saavedra J: Gallbladder adenomas have molecular abnormalities different from those present in gallbladder carcinomas. Hum Pathol 1999, 30:21-25
8. Wistuba II, Albores-Saavedra J: Genetic abnormalities involved in the pathogenesis of gallbladder carcinoma. J Hepatobiliary Pancreat Surg 1999, 6:237-244
9. Sasatomi E, Tokunaga O, Miyazaki K: Precancerous conditions of gallbladder carcinoma: overview of histopathologic characteristics and molecular genetic findings. J Hepatobiliary Pancreat Surg 2000, 7:556-567
10. Nakanuma Y, Harada K, Ishikawa A, Zen Y, Sasaki M: Anatomic and molecular pathology of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 2003, 10:265-281 (Pubitemid 37407516)
11. Rashid A: Cellular and molecular biology of biliary tract cancers. Surg Oncol Clin N Am 2002, 11:995-1009 (Pubitemid 35397235)
12. Wang Y, Yamaguchi Y, Watanabe H, Ohtsubo K, Wakabayashi T, Sawabu N: Usefulness of p53 gene mutations in the supernatant of bile for diagnosis of biliary tract carcinoma: comparison with K- ras mutation. J Gastroenterol 2002, 37:831-839 (Pubitemid 35390303)
13. Shi CES, Jones D, Fukushima N, Hua L, Parker AR, Yeo CJ, Hruban RH, Goggins MG, Eshleman JR: LigAmp: sensitive detection of single nucleotide differences. Nature Meth 2004, 1:141-147
14. Shi C, Fukushima N, Abe T, Bian Y, Hua L, Wendelburg BJ, Yeo CJ, Hruban RH, Goggins MG, Eshleman JR: Sensitive and quantitative detection of KRAS2 gene mutations in pancreatic duct juice differentiates patients with pancreatic cancer from chronic pancreatitis, potential for early detection. Cancer Biol Ther 2008, 7:353-360 (Pubitemid 351847047)
15. Al-Soud WA, Ouis IS, Li DQ, Ljungh S, Wadstrom T: Characterization of the PCR inhibitory effect of bile to optimize real-time PCR detection of Helicobacter species. FEMS Immunol Med Microbiol 2005, 44:177-182
16. Yachimski P, Pratt DS: Cholangiocarcinoma: natural history, treatment, and strategies for surveillance in high-risk patients. J Clin Gastroenterol 2008, 42:178-190
17. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM: Biliary tract cancers. N Engl J Med 1999, 341:1368-1378
18. Shaib Y, El-Serag HB: The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004, 24:115-125
19. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD: Cholangiocarcinoma. Lancet 2005, 366:1303-1314
20. Mariyama M, Kishi K, Nakamura K, Obata H, Nishimura S: Frequency and types of point mutation at the 12th codon of the c-Ki-ras gene found in pancreatic cancers from Japanese patients. Jpn J Cancer Res 1989, 80:622-626 (Pubitemid 20036000)
21. Levi S, Urbano-Ispizua A, Gill R, Thomas DM, Gilbertson J, Foster C, Marshall CJ: Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. Cancer Res 1991, 51:3497-3502
22. Laghi L, Orbetegli O, Bianchi P, Zerbi A, Di Carlo V, Boland CR, Malesci A: Common occurrence of multiple K-RAS mutations in pancreatic cancers with associated precursor lesions and in biliary cancers. Oncogene 2002, 21:4301-4306 (Pubitemid 34753836)
23. Nehls O, Gregor M, Klump B: Serum and bile markers for cholangiocarcinoma. Semin Liver Dis 2004, 24:139-154
24. Bonney GK, Craven RA, Prasad R, Melcher AF, Selby PJ, Banks RE: Circulating markers of biliary malignancy: opportunities in proteomics? Lancet Oncol 2008, 9:149-158
25. Albert MB, Steinberg WM, Henry JP: Elevated serum levels of tumor marker CA19-9 in acute cholangitis. Dig Dis Sci 1988, 33:1223-1225
26. Kristiansen TZ, Harsha HC, Gronborg M, Maitra A, Pandey A: Differential membrane proteomics using 18O-labeling to identify biomarkers for cholangiocarcinoma. J Proteome Res 2008, 7:4670-4677
27. Kristiansen TZ, Bunkenborg J, Gronborg M, Molina H, Thuluvath PJ, Argani P, Goggins MG, Maitra A, Pandey A: A proteomic analysis of human bile. Mol Cell Proteomics 2004, 3:715-728
28. Koopmann J, Thuluvath PJ, Zahurak ML, Kristiansen TZ, Pandey A, Schulick R, Argani P, Hidalgo M, Iacobelli S, Goggins M, Maitra A: Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma. Cancer 2004, 101:1609-1615 (Pubitemid 39318908)
29. Caldas C: Biliopancreatic malignancy: screening the at risk patient with molecular markers. Ann Oncol 1999, 10:153-156
30. Saurin JC, Joly-Pharaboz MO, Pernas P, Henry L, Ponchon T, Madjar JJ: Detection of Ki-ras gene point mutations in bile specimens for the differential diagnosis of malignant and benign biliary strictures. Gut 2000, 47:357-361 (Pubitemid 30670828)
31. Kubicka S, Kuhnel F, Flemming P, Hain B, Kezmic N, Rudolph KL, Manns M, Meier PN: K-ras mutations in the bile of patients with primary sclerosing cholangitis. Gut 2001, 48:403-408 (Pubitemid 32269571)